Rhythm Pharmaceuticals Inc. (RYTM)
RYTM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1649904/000162828026012399/0001628280-26-012399-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | RYTM on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2017 |
| SEC CIK | 0001649904 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $189.8M |
| Net income | -$196.5M |
| Operating income | -$192.0M |
| Net margin | -103.6% |
| Operating margin | -101.2% |
| Revenue growth | +45.8% |
| Cash | $54.3M |
| Total assets | $480.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 39.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-03 |
| Cash and burn | $40.0M cash; operating cash flow -$20.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 69,330,906 (2026-11-02); 66,736,056 a year earlier; 59,096,454 three years earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-02-26 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $41.7M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $92.1M | -$41.4M | -$3.1M | $40.0M | $102.7M | $280.7M | 10-Q 2026-11-03 |
| Q2 2026 2026-06-30 | $71.3M | -$49.3M | -$9.2M | $65.6M | $106.1M | $239.9M | 10-Q 2026-08-04 |
| Q1 2026 2026-03-31 | $60.1M | -$55.6M | -$44.2M | $62.1M | $108.5M | $217.2M | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | $57.3M | -$47.5M | -$25.4M | $54.3M | $108.2M | $189.8M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $51.3M | -$52.9M | -$26.6M | $52.1M | $109.0M | $174.3M | 10-Q 2026-11-03 |
| Q2 2025 2025-06-30 | $48.5M | -$46.6M | -$23.3M | $135.6M | $109.8M | $156.3M | 10-Q 2026-08-04 |
| Q1 2025 2025-03-31 | $32.7M | -$49.5M | -$40.4M | $106.1M | $109.5M | $136.9M | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | $41.8M | -$43.3M | -$18.8M | $89.1M | $109.8M | $130.1M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-02-26 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-03 |
| Latest current report | 8-K | 2026-11-03 |
| Latest proxy | DEFA14A | 2026-05-29 |
Source: SEC EDGAR submissions feed, 837 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.4% |
| 1 month | +32.8% |
| 3 months | -0.9% |
| Year to date | +7.5% |
| 1 year | +19.9% |
| From 52-week high | -2.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CYTK | Cytokinetics Incorporated | $53.17 | -5.27% | $7.4B |
| KNSA | Kiniksa Pharmaceuticals International plc | $94.23 | -2.18% | $7.4B |
| AMRX | Amneal Pharmaceuticals Inc. | $21.23 | -0.70% | $7.4B |
| CORT | Corcept Therapeutics Incorporated | $69.22 | -5.10% | $7.6B |
| ABVX | Abivax SA | $83.61 | -4.53% | $7.3B |
| AXSM | Axsome Therapeutics Inc. | $137.01 | -3.30% | $7.2B |
| ALKS | Alkermes plc | $46.53 | -1.06% | $7.8B |
| PTGX | Protagonist Therapeutics Inc. | $124.83 | -4.67% | $8.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier